Injection site reactions are the most commonly reported dermatological effects with subcutaneous semaglutide (Ozempic and Wegovy) and typically present as redness, itching, bruising, or mild swelling at the site of administration
Oxytocin adds tissue healing properties and has emerging evidence for gut-brain axis tuning and anti-swelling effects
Semaglutide and tirzepatide are commonly mentioned in medically supervised weight loss
#IndianPharma #PharmaSector #ChronicCare #HealthcareTrends #LongTermGrowth #ShareIndia #ShareIndiaResearch To view or add a comment, sign in A new real-world study by analytics firm nference shows that a notable portion of patients may sustain weight loss even after stopping GLP-1 obesity drugs from Novo Nordisk and Eli Lilly, Reuters reported
Syrup Depakene by Abbott Laboratories
Many individuals lose around 5% to 10% of their starting body weight after six months to a year of consistent treatment, especially when combined with dietary improvements and increased physical activity